Table 3.

ICIs approved and on ongoing clinical evaluation for advanced NSCLC patients.

Drug	Target(S)	Indications	FDA Approval	Ref.
Pembrolizumab KEYTRUDA®	PD-1	First-line systemic therapy for NSCLC patients with PD-L1 expression > 50% and without EGFR or ALK mutations Second-line advanced stage NSCLC after progression on first-line chemotherapy (PD-L1 > 1%) First-line for metastatic non-squamous NSCLC in combination with pemetrexed and carboplatin (regardless of PD-L1 expression)	2015 2015 2017	[66] [67]
Nivolumab OPDIVO®	PD-1	Advanced squamous and non-squamous NSCLC as second-line systemic therapy after progression on first-line chemotherapy (regardless of PD-L1 expression) First-line treatment for metastatic or recurrent NSCLC without EGFR or ALK mutations, in combination with Ipilimumab YERVOY® (anti CTLA-4) and 2 cycles of platinum-doublet chemotherapy	2015 2020	[68] [69]
Durvalumab IMFINZI®	PD-L1	Unresectable stage III NSCLC patients that have not progressed after chemoradiation therapy	2018	[70]
Atezolizumab TECENTRIQv	PD-L1	First-line treatment in metastatic NSCLC with PD-L1 > 50%	2020	[71]
Cemiplimab-rwlcLIBTAYO®	PD-1	First-line treatment in locally or metastatic advanced stage NSCLC (no eligible to surgical resection nor definitive chemoradiation) with PD-L1 > 50%	2021	[72]